Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection
Importance
SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals.
Objective
To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections.
Design, Setting, and Participants
Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling.
Exposure
SARS-CoV-2 infection.
Main Outcomes and Measures
PASC and 44 participant-reported symptoms (with severity thresholds).
Results
A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months.
Conclusions and Relevance
A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.
Top-30
Journals
|
5
10
15
20
|
|
|
PLoS ONE
20 publications, 3.06%
|
|
|
Nature Communications
15 publications, 2.29%
|
|
|
Scientific Reports
14 publications, 2.14%
|
|
|
JAMA network open
14 publications, 2.14%
|
|
|
Frontiers in Immunology
9 publications, 1.38%
|
|
|
JAMA - Journal of the American Medical Association
8 publications, 1.22%
|
|
|
BMJ Open
8 publications, 1.22%
|
|
|
medRxiv : the preprint server for health sciences
7 publications, 1.07%
|
|
|
Vaccines
6 publications, 0.92%
|
|
|
BMC Infectious Diseases
6 publications, 0.92%
|
|
|
Frontiers in Medicine
6 publications, 0.92%
|
|
|
Open Forum Infectious Diseases
6 publications, 0.92%
|
|
|
Healthcare
6 publications, 0.92%
|
|
|
American Journal of Medicine
6 publications, 0.92%
|
|
|
Journal of Clinical Medicine
6 publications, 0.92%
|
|
|
COVID
6 publications, 0.92%
|
|
|
Brain Behavior & Immunity - Health
6 publications, 0.92%
|
|
|
Biomedicines
5 publications, 0.76%
|
|
|
International Journal of Infectious Diseases
5 publications, 0.76%
|
|
|
Clinical Microbiology and Infection
5 publications, 0.76%
|
|
|
Frontiers in Neurology
5 publications, 0.76%
|
|
|
BMC Medicine
5 publications, 0.76%
|
|
|
Annals of Internal Medicine
5 publications, 0.76%
|
|
|
Brain, Behavior, and Immunity
4 publications, 0.61%
|
|
|
International Journal of Molecular Sciences
4 publications, 0.61%
|
|
|
Microorganisms
4 publications, 0.61%
|
|
|
Research square
4 publications, 0.61%
|
|
|
Frontiers in Pediatrics
4 publications, 0.61%
|
|
|
Nature Immunology
4 publications, 0.61%
|
|
|
5
10
15
20
|
Publishers
|
20
40
60
80
100
120
140
|
|
|
Elsevier
139 publications, 21.25%
|
|
|
Springer Nature
112 publications, 17.13%
|
|
|
MDPI
57 publications, 8.72%
|
|
|
Cold Spring Harbor Laboratory
44 publications, 6.73%
|
|
|
Wiley
37 publications, 5.66%
|
|
|
Frontiers Media S.A.
37 publications, 5.66%
|
|
|
American Medical Association (AMA)
25 publications, 3.82%
|
|
|
Public Library of Science (PLoS)
25 publications, 3.82%
|
|
|
Oxford University Press
22 publications, 3.36%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
20 publications, 3.06%
|
|
|
Taylor & Francis
18 publications, 2.75%
|
|
|
BMJ
13 publications, 1.99%
|
|
|
SAGE
11 publications, 1.68%
|
|
|
Research Square Platform LLC
5 publications, 0.76%
|
|
|
European Respiratory Society (ERS)
5 publications, 0.76%
|
|
|
American College of Physicians
5 publications, 0.76%
|
|
|
JMIR Publications
5 publications, 0.76%
|
|
|
Georg Thieme Verlag KG
4 publications, 0.61%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 0.61%
|
|
|
Bentham Science Publishers Ltd.
3 publications, 0.46%
|
|
|
S. Karger AG
3 publications, 0.46%
|
|
|
Spandidos Publications
2 publications, 0.31%
|
|
|
The American Association of Immunologists
2 publications, 0.31%
|
|
|
Association for Computing Machinery (ACM)
2 publications, 0.31%
|
|
|
Massachusetts Medical Society
2 publications, 0.31%
|
|
|
American Chemical Society (ACS)
2 publications, 0.31%
|
|
|
Mary Ann Liebert
2 publications, 0.31%
|
|
|
The American Academy of Sleep Medicine
2 publications, 0.31%
|
|
|
20
40
60
80
100
120
140
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.